



#47

(Modified) PTO/SB/63 (08-03)
Approved for use through 07/31/2006 OMB 0651-0031

TERMINAL DISCLAIMER TO ACCOMPANY PETITION

Docket Number (Optional)
402E-978316US

In re Application of: Phillip W. Berman et al.

Application No. 08/459,141

Filed: June 2, 1995

IMMUNOGENIC COMPOSITION BASED ON A TRUNCATED DERIVATIVE OF A MEMBRANE
BOUND PROTEIN AND PROCESS FOR MAKING IT

The owner*, Genentech, Inc. of 100 percent interest in the subject application hereby disclaims a terminal part of the term of any patent granted the above-identified application equivalent to the period of abandonment of the subject application only to the extent that such disclaimer is required for revival of the subject application.

This disclaimer also applies to any patent granted on a utility or plant application filed before June 8, 1995, or a design application, that contains a specific reference under 35 U.S.C. 120, 121, or 365(c) to the above-identified application. This disclaimer is binding upon the grantee, and its successors or assigns.

Check either box 1 or 2 below, if appropriate

1. For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.
2. The undersigned is an attorney of record.



Signature

1-23-04

Date

Jonathan Alan Quine Reg. No. 41,261 for

Emily M. Haliday, Reg. No. 38,903

Typed or printed name

Terminal disclaimer fee under 37 CFR 1.20(d) is included (fee transmittal attached).

*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).
Form PTO/SB/96 may be used for making this certification. See MPEP §324.

01/29/2004 AWONDAF1 00000032 500893 08459141

03 FC:1814

110.00 DA